Department of Surgery, Division of General and Sport Traumatology and Orthopaedics, Merkur University Hospital, Zagreb, Croatia.
Department of Internal Medicine, Division of Nephrology and Dialysis, Dubrava University Hospital, Zagreb, Croatia.
Growth Factors. 2024 Feb;42(1):1-12. doi: 10.1080/08977194.2023.2274579. Epub 2024 Jan 31.
Fibroblast growth factor 23 (FGF23) has been casually linked to numerous hypophosphatemic bone diseases, however connection with bone loss or fragility fractures is still a matter of debate. The purpose of this review is to explore and summarise the known actions of FGF23 in various pathological bone conditions. Besides implication in bone mineralisation, elevated FGF23 showed a pathological effecton bone remodelling, primarily by inhibiting osteoblast function. Unlike the weak association with bone mineral density, high values of FGF23 have been connected with fragility fracture prevalence. This review shows that its effects on bone are concomitantly present on multiple levels, affecting both qualitative and quantitative part of bone strength, eventually leading to impaired bone strength and increased tendency of fractures. Recognising FGF23 as a risk factor for the development of bone diseases and correcting its levels could lead to the reduction of morbidity and mortality in specific groups of patients.
成纤维细胞生长因子 23（FGF23）与许多低磷血症性骨疾病有关，但与骨丢失或脆性骨折的联系仍存在争议。本综述的目的是探讨和总结 FGF23 在各种病理骨状况中的已知作用。除了在骨矿化中的作用外，升高的 FGF23 对骨重塑也有病理影响，主要通过抑制成骨细胞功能。与骨密度的弱相关性不同，高 FGF23 值与脆性骨折的发生率有关。本综述表明，其对骨骼的影响同时存在于多个层面，影响骨骼强度的定性和定量部分，最终导致骨骼强度降低和骨折风险增加。将 FGF23 视为骨骼疾病发展的危险因素，并纠正其水平，可能会降低特定患者群体的发病率和死亡率。
